Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Michael Moyle

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Biotechnology Advances|March 15, 2017
Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccinesPeter Michael Moyle
Current Protocols in Microbiology|February 3, 2015
Progress in vaccine developmentPeter Michael Moyle
Bioconjugate Chemistry|September 12, 2017
Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor LigandsZhenghui Xu, Peter Michael Moyle
Chempluschem|January 17, 2020
A Self-Adjuvanting Vaccine Platform: Optimization of Site-Specific Sortase A Mediated Conjugation of Toll-Like Receptor 2 Ligands onto the Carboxyl or Amino terminus of Recombinant Protein AntigensZhenghui Xu, Peter Michael Moyle
Chemmedchem|January 15, 2013
Modern subunit vaccines: development, components, and research opportunitiesPeter Michael Moyle, Istvan Toth
ACS Infectious Diseases|May 15, 2020
Development of an Enzyme-Mediated, Site-Specific Method to Conjugate Toll-Like Receptor 2 Agonists onto Protein Antigens: Toward a Broadly Protective, Four Component, Group A Streptococcal Self-Adjuvanting Lipoprotein-Fusion Combination VaccineZhenghui Xu, Tania Rivera-Hernandez, Peter Michael Moyle
Bioorganic & Medicinal Chemistry|November 28, 2021
Optimized protocols for assessing libraries of poorly soluble sortase A inhibitors for antibacterial activity against medically-relevant bacteria, toxicity and enzyme inhibitionSitah Alharthi, Zyta Maria Ziora, Peter Michael Moyle
Cells|May 13, 2026
Interplay Between TLR4 and Gelatinases in Tumour Growth and MetastasisAbdulfattah Al-Kadash, Peter Michael Moyle, Marie-Odile Parat
Drug Discovery Today|October 13, 2024
Advances in, and prospects of, 3D preclinical models for skin drug discoveryMohammad Imran, Peter Michael Moyle, Danielle Kamato, et al.
Molecules (Basel, Switzerland)|March 11, 2023
Sortase A Inhibitor Protein Nanoparticle Formulations Demonstrate Antibacterial Synergy When Combined with Antimicrobial PeptidesSitah Alharthi, Amirali Popat, Zyta Maria Ziora, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Biotechnology Advances|March 15, 2017
Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccinesPeter Michael Moyle
Current Protocols in Microbiology|February 3, 2015
Progress in vaccine developmentPeter Michael Moyle
Bioconjugate Chemistry|September 12, 2017
Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor LigandsZhenghui Xu, Peter Michael Moyle
Chempluschem|January 17, 2020
A Self-Adjuvanting Vaccine Platform: Optimization of Site-Specific Sortase A Mediated Conjugation of Toll-Like Receptor 2 Ligands onto the Carboxyl or Amino terminus of Recombinant Protein AntigensZhenghui Xu, Peter Michael Moyle
Chemmedchem|January 15, 2013
Modern subunit vaccines: development, components, and research opportunitiesPeter Michael Moyle, Istvan Toth
ACS Infectious Diseases|May 15, 2020
Development of an Enzyme-Mediated, Site-Specific Method to Conjugate Toll-Like Receptor 2 Agonists onto Protein Antigens: Toward a Broadly Protective, Four Component, Group A Streptococcal Self-Adjuvanting Lipoprotein-Fusion Combination VaccineZhenghui Xu, Tania Rivera-Hernandez, Peter Michael Moyle
Bioorganic & Medicinal Chemistry|November 28, 2021
Optimized protocols for assessing libraries of poorly soluble sortase A inhibitors for antibacterial activity against medically-relevant bacteria, toxicity and enzyme inhibitionSitah Alharthi, Zyta Maria Ziora, Peter Michael Moyle
Cells|May 13, 2026
Interplay Between TLR4 and Gelatinases in Tumour Growth and MetastasisAbdulfattah Al-Kadash, Peter Michael Moyle, Marie-Odile Parat
Drug Discovery Today|October 13, 2024
Advances in, and prospects of, 3D preclinical models for skin drug discoveryMohammad Imran, Peter Michael Moyle, Danielle Kamato, et al.
Molecules (Basel, Switzerland)|March 11, 2023
Sortase A Inhibitor Protein Nanoparticle Formulations Demonstrate Antibacterial Synergy When Combined with Antimicrobial PeptidesSitah Alharthi, Amirali Popat, Zyta Maria Ziora, et al.
Pageof 2